Park Ha Biological Technology Co., Ltd. disclosed details of its proposed 1-for-50 reverse stock split of Class A and Class B ordinary shares, which was approved by shareholders on December 26, 2025, and expects the split to become effective on February 20, 2026. The disclosure includes the company's issued and outstanding share capital before and after the proposed reverse split.
Key takeaways
The company plans a 1-for-50 reverse stock split of its Class A and Class B ordinary shares.
Shareholders approved the reverse split at an extraordinary meeting held on December 26, 2025.
The board of directors approved the exact reverse split ratio on January 29, 2026.
The reverse split is expected to become effective on February 20, 2026, with trading on a split-adjusted basis beginning at market open that day.
Pre-split share capital consists of 104,768,362 ordinary shares (85,718,362 Class A, 19,050,000 Class B).
Post-split share capital is expected to be 2,095,368 ordinary shares (1,714,368 Class A, 381,000 Class B).
No fractional shares will be issued; all fractional shares will be rounded up to the nearest whole share.
No other material changes to the terms of the company's securities are anticipated in connection with the reverse split.